Elevance Health Q1 EPS rises 15.5% to $9.59 and raises 2024 EPS outlook
Elevance Health reported first quarter 2024 results on April 18, 2024, with operating revenue of $42.3 billion, up 0.9% from a year earlier, and diluted EPS of $9.59, up 15.5%. The company raised its full-year 2024 guidance to diluted EPS greater than $34.05 and adjusted diluted EPS greater than $37.20, which signals stronger expected earnings for shareholders.
- Q1 2024 diluted EPS was $9.59, up 15.5%; adjusted diluted EPS was $10.64, up 12.5%
- Operating revenue was $42.3 billion, up 0.9%; total operating margin was 7.1%, up 30 basis points
- Full-year 2024 diluted EPS guidance raised to greater than $34.05; adjusted diluted EPS guidance raised to greater than $37.20
- Repurchased 1.1 million shares for $566 million in Q1; quarterly dividend of $1.63 per share declared, payable June 25, 2024